Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

BACKGROUND: The bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant gliom...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Artene, Stefan-Alexandru, Turcu-Stiolica, Adina, Hartley, Richard, Ciurea, Marius Eugen, Daianu, Oana, Brindusa, Corina, Alexandru, Oana, Tataranu, Ligia Gabriela, Purcaru, Stefana Oana, Dricu, Anica
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2016
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5108618/
https://ncbi.nlm.nih.gov/pubmed/27877052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S112842
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items